Bill Ackman

Bill Ackman’s Pershing Square Tontine special purpose acquisition company entered the market on Tuesday above its original pricing.
Pershing Square Tontine Holdings has filed with the SEC regarding its initial public offering.
Herbalife has been more than a controversial stock over the past three years or more. Short seller and activist investor Bill Ackman had roughly a $1 billion bet against this company and has been a...
Carl Icahn believes that Herbalife might be better off as a privately held firm and he has weighed the possibility of launching a tender offer for it.
Although some analysts have become less negative and upgraded to a more neutral view on Valeant Pharmaceuticals, Morgan Stanley's is a true call to buy the stock.
Herbalife is treating this settlement as a victory. The question now is whether it will begin to aggressively go after Bill Ackman for calling Herbalife a pyramid scheme.
Insiders looking to sell shares are starting to emerge from the sidelines as quiet periods are ending, including activist investor Bill Ackman.
Canadian Pacific Railway released details Wednesday morning of a hostile takeover offer for U.S.-based railroad operator Norfolk Southern.
Is it possible that activist investors now have just too much money under their management and are simply biting off more than they can chew?
Herbalife reported better-than-expected first-quarter financial results after the markets closed Tuesday.
A new Moody's report suggests, or warns, that shareholder activism continues to rise and that this trend could have negative implications for credit investors.
Shares of Herbalife may still be way down from when activist investor Bill Ackman first publicly went after the maker of vitamins and health products, but they have also bounced handily of late.
In the ongoing battle of Bill Ackman versus Herbalife, it appears that Herbalife has struck a decisive blow.
Herbalife was under attack yet again on Friday morning by activist investor Bill Ackman on an appearance on CNBC.
Canaccord Genuity maintained its Buy rating for Herbalife but lowered its price target to $42 from $50, noting that the company is starting to feel like a value trap.